In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be used in cancer medicine. This video introduces roles for magnetic relaxometry in early cancer detection, cancer staging, and therapeutic monitoring. It also outlines the unique capabilities of magnetic relaxometry relative to MRI, ultrasound, X-ray imaging, blood biomarkers, and biopsies.
Imagion Biosystems HER2 Breast Cancer Program Update
October 7, 2025
Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,